These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 20531311)
21. Prostate cancer vaccines. Michael A; Relph K; Annels N; Pandha H Expert Rev Vaccines; 2013 Mar; 12(3):253-62. PubMed ID: 23496665 [TBL] [Abstract][Full Text] [Related]
22. Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches. Arlen PM Oncology (Williston Park); 2011 Mar; 25(3):261-2. PubMed ID: 21548469 [No Abstract] [Full Text] [Related]
23. Cancer vaccine approval could open floodgates. Nat Med; 2010 Jun; 16(6):615. PubMed ID: 20526296 [No Abstract] [Full Text] [Related]
24. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Buonerba C; Ferro M; Di Lorenzo G Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508 [TBL] [Abstract][Full Text] [Related]
25. The role of complement in dendritic cell (DC) control of T-cell subsets. Levis WR; Martiniuk F J Drugs Dermatol; 2010 Nov; 9(11):1364-6. PubMed ID: 21061758 [TBL] [Abstract][Full Text] [Related]
32. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. Antonarakis ES; Kibel AS; Yu EY; Karsh LI; Elfiky A; Shore ND; Vogelzang NJ; Corman JM; Millard FE; Maher JC; Chang NN; DeVries T; Sheikh NA; Drake CG; Clin Cancer Res; 2017 May; 23(10):2451-2459. PubMed ID: 27836866 [No Abstract] [Full Text] [Related]
33. Immunotherapy: a new option for advanced prostate cancer. Harv Mens Health Watch; 2010 Sep; 15(2):1-2. PubMed ID: 20941869 [No Abstract] [Full Text] [Related]
34. Prostate cancer immunology - an update for Urologists. Rajarubendra N; Lawrentschuk N; Bolton DM; Klotz L; Davis ID BJU Int; 2011 Apr; 107(7):1046-51. PubMed ID: 21070575 [TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg? Laccetti AL; Subudhi SK Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923 [TBL] [Abstract][Full Text] [Related]
36. Combining immunotherapies for the treatment of prostate cancer. Redman JM; Gulley JL; Madan RA Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441 [TBL] [Abstract][Full Text] [Related]
38. Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer. Sutherland SIM; Ju X; Horvath LG; Clark GJ Front Immunol; 2021; 12():641307. PubMed ID: 33854509 [TBL] [Abstract][Full Text] [Related]
39. The evolving role of immunotherapy in prostate cancer. Gerritsen WR Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924 [TBL] [Abstract][Full Text] [Related]
40. Immunotherapeutic approaches in prostate cancer: combinations and clinical integration. Slovin SF Am Soc Clin Oncol Educ Book; 2015; ():e275-83. PubMed ID: 25993186 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]